The California Technology Assessment Forum (CTAF), a core program of the Institute for Clinical and Economic Review (ICER), is a nationally-recognized community forum. CTAF convenes three times each year at public meetings to review objective evidence reports and develop recommendations for how stakeholders can apply evidence to improve the quality and value of health care. Learn more about the CTAF process, and find out how topics are selected. CTAF directly engages clinicians, patients, and payers during public meetings to discuss implications of the evidence for clinical decision-making and coverage policies. Application of evidence takes shape through new medical policies, benefit designs, and patient and clinician tools to improve clinical care and patient outcomes. All members of the CTAF Panel must meet ICER's criteria for Conflict of Interest. For CTAF reports published prior to September 2013, please email info@icer-review.org The box below provides information on the topic of the next meeting of CTAF. For more information about past and other upcoming meetings, see the box to the right.

Next Meeting

March 2, 2018 10am-4pm PT

California, TBD

CAR-T Therapies

The California Technology Assessment Forum will convene to discuss evidence on CAR-T therapies.


CAR-T Therapies

ICER will develop a report on chimeric antigen receptor t-cell (CAR-T) therapies for treatment of B-cell malignancies. ICER’s report is expected to consider the comparative clinical effectiveness and value of tisagenlecleucel (KymriahTM [CTL-019], Novartis) and axicabtagene ciloleucel (KTE-019, Kite Pharma). Tisagenlecleucel was approved by the FDA is August of 2017; an approval decision for axicabtagene ciloleucel is expected in December of 2017, respectively.  If approved, tisagenlecleucel-t is expected to be used in the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia in pediatric and young adult patients. Novartis is also expected to file later this year for a second indication for diffuse large B-cell lymphoma in adults. Axicabtagene ciloleucel is under review for the treatment of relapsed or refractory aggressive non-Hodgkin’s lymphoma in adult patients who are not eligible for autologous stem cell transplant.

Date of Review: March 2018

View materials